Sixty firms' business worth Rs 1,000 crore at stake.
The company recorded a net profit of Rs 426.9 crore (Rs 4.26 billion) in the first nine months against Rs 366.5 crore (Rs 3.66 billion) for the same period in 2006. With another quarter to go, the company expects profits close to Rs 739.3 crore (Rs 7.39 billion).
Of the top-10 global biotech companies, the biggest two -- Amgen and Biogen -- have already set up wholly owned subsidiaries in the country.
The process started from October 6, and trademark owners have the chance to register domain names in the new .asia top-level domain (TLD), prior to a general release of .asia names in 2008. With the support of 73 countries in the region, .asia is looking at means to bind the Asian community.
Rising wage costs, competition from countries like China, the impending withdrawal of tax incentives under the STPI scheme, the slowdown in the US and the rising rupee have all punctured the optimism of the IT industry.
The medicines whose prices have been reduced belong to therapeutic categories, like dexametozone, betamethazone, ampicillin and ranitidine. The prices of some multi-vitamins and antibiotics would rise a bit.
The R&D plan, focused on diseases affecting poor nations, is expected to be ready by 2008 and may benefit Indian drug firms and contract research organisations in a big way.
Computer hardware majors like Dell, HP and HCL launch products to woo companies.
The PhRMA's observation is significant against the backdrop of Swiss pharma major Novartis AG's decision to relocate its R&D investments from India.
The patent department made this declaration on August 16 after Novartis had failed to respond to its queries within the prescribed time.
The profit margins of multinational companies importing medicines into India have been hit with the National Pharmaceutical Pricing Authority starting strict scrutiny of price approval applications for imported products.
Indian exporters of ayurvedic drugs are finding it extremely difficult to tap this high-growth segment
According to a petition filed by Quadrant in the Delhi High Court, Travel Guru allegedly copied its software solution 'Final Quadrant SuiteCase'.
Absence of operational manual that guides examiners, heavy backlog take a toll.
Indian pharmaceutical companies exporting medicines worth $1 billion to at least a dozen countries like Brazil, Mexico, China and Germany are finding non-tariff barriers, in the form of discriminatory treatments, hampering their export prospect.
Besides Novartis, the other companies are Roche, J&J, Glaxo and Astrazeneca.
This has prompted public health groups to call the concerns of Swiss drug major Novartis that inadequacies in Indian patent law will have negative consequences for patients and public health in India as 'bogus'.
The industry is non-committal on whether it is particularly vulnerable.
Thursday's flooding of the National Informatics Centre rendered most of the Indian government websites with the domain address 'nic.in' -- including the Prime Minister's and President's websites -- inaccessible.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances